Table of Content - Diabetic Kidney Disease Market

Global diabetic kidney disease market is estimated to be valued at USD 3.03 Bn in 2024 and is expected to exhibit a CAGR of 4.8% during the forecast period (2024-2031). Diabetic kidney disease (DKD) is a condition in which the kidneys are damaged due to long-standing diabetes. Over time, high blood sugar from diabetes can damage both the small blood vessels in the kidneys as well as the filtering units (glomeruli) within the kidneys. Damage to the glomeruli can reduce kidney function and may lead to kidney failure, if not controlled effectively. With increasing prevalence of diabetes globally, the market for treatments of diabetic kidney disease is projected to grow steadily in the near future.

Market Dynamics:

Global diabetic kidney disease market is witnessing significant growth due to rising prevalence of diabetes and obesity worldwide. Some of the key drivers fueling the market growth include growing geriatric population who are more susceptible to chronic kidney diseases, rising awareness about early diagnosis and treatment of DKD, and increasing U.S. FDA approvals of novel drugs to treat DKD. However, factors such as high costs associated with kidney failure treatments and lack of diseases awareness in low-income regions can hamper the market growth. Ongoing R&D efforts to develop more efficacious drugs with improved safety profiles provide lucrative opportunities for market players. Increasing health expenditures of governments worldwide on kidney care is anticipated to create a positive business environment during the forecast period.

Key Features of the Study:

This report provides in-depth analysis of the global diabetic kidney disease market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global diabetic kidney disease market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, and Vertex Pharmaceuticals Incorporated.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global diabetic kidney disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic kidney disease market.

Detailed Segmentation-

Drug Class:
- Angiotensin Receptor Blockers (ARBs)
- Calcium Channel Blockers
- Antioxidant Inflammation Modulator
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Others
Route of Administration:
- Oral
- Parenteral
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug Class
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
Global Diabetic Kidney Disease Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
Global Diabetic Kidney Disease Market, By Drug Class, 2019 – 2031, (USD BN)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2019 – 2031
  - Segment Trends
- Angiotensin Receptor Blockers (ARBs)
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Calcium Channel Blockers
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Antioxidant Inflammation Modulator
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Angiotensin-Converting Enzyme (ACE) Inhibitors
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Others
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
Global Diabetic Kidney Disease Market, By Route of Administration, 2019 – 2031, (USD BN)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2019 – 2031
  - Segment Trends
- Oral
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Parenteral
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
Global Diabetic Kidney Disease Market, By Distribution Channel, 2019 – 2031, (USD BN)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2019 – 2031
  - Segment Trends
- Hospital Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Retail Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
- Online Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD BN)
Global Diabetic Kidney Disease Market, By Region, 2019 – 2031, (USD BN)
- Introduction
  - Market Share Analysis, By Region, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, For Region, 2019–2031
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (USD BN)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - AstraZeneca
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Boehringer Ingelheim
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Janssen Pharmaceuticals
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Bristol Myers Squibb
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - GSK
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Novo Nordisk
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Eli Lilly and Company
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Merck & Co.
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Sanofi
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - AbbVie
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Sun Pharmaceutical Industries Ltd
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Teva Pharmaceutical Industries Ltd
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Lupin
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Aurobindo Pharma
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Takeda Pharmaceutical Company Limited
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Biogen
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Vertex Pharmaceuticals Incorporated
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact

*Browse 36 market data tables and 48 figures on "Diabetic Kidney Disease Market” -Global forecast to 2031

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount